Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Tscan Therapeutics Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. LEE, YIE CHIA is the busiest examiner, handling 1 pending office action. The equal distribution of cases across different examiners and art units suggests a diversified prosecution strategy for the company's current patent applications in this sector.
This prosecution profile shows a high degree of diversity, as each of the 3 pending office actions is being reviewed by a different individual in a different administrative unit. Such a spread is beneficial for mitigating the risk associated with any single examiner's tendencies or any single art unit's policies. However, it also requires the practitioner to manage three distinct relationships and sets of procedural expectations. Coordinating claim language across these 3 distinct art units is essential to ensure that the resulting patents provide broad and consistent protection for the company's biotechnology innovations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| AMICK, THOMAS RUSSE | 1 | 73.8% | +29.4% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035373 | BINDING PROTEINS RECOGNIZING HA-1 ANTIGEN AND USES THEREOF | LEE, YIE CHIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035373 | BINDING PROTEINS RECOGNIZING HA-1 ANTIGEN AND USES THEREOF | LEE, YIE CHIA | — |
| 18011577 | COMPOSITIONS AND METHODS FOR IDENTIFYING EPITOPES | AMICK, THOMAS RUSSE | — |
| 17984639 | BINDING PROTEINS RECOGNIZING HPV16 E7 ANTIGEN AND USES THEREOF | DRISCOLL, MAUREEN VARINA | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1638 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18035373 | BINDING PROTEINS RECOGNIZING HA-1 ANTIGEN AND USES THEREOF | LEE, YIE CHIA | 1642 | §101§102§103§112 | Non-Final OA | — | Pending | May 04, 2023 |
| 18011577 | COMPOSITIONS AND METHODS FOR IDENTIFYING EPITOPES | AMICK, THOMAS RUSSE | 1638 | §103 | Non-Final OA | — | Pending | Dec 20, 2022 |
| 17984639 | BINDING PROTEINS RECOGNIZING HPV16 E7 ANTIGEN AND USES THEREOF | DRISCOLL, MAUREEN VARINA | 1644 | §112DP | Non-Final OA | — | Pending | Nov 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTscan Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Yie Chia Lee has the most, with 1 of Tscan Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
